Singapore markets closed

Protalix BioTherapeutics, Inc. (PLX)

NYSE American - NYSE American Delayed price. Currency in USD
Add to watchlist
1.1000-0.1500 (-12.00%)
At close: 04:00PM EDT
1.0900 -0.01 (-0.91%)
After hours: 07:47PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.2500
Open1.0400
Bid1.0500 x 800
Ask1.1300 x 800
Day's range1.0308 - 1.1400
52-week range1.0300 - 2.5100
Volume2,177,573
Avg. volume424,252
Market cap80.648M
Beta (5Y monthly)0.90
PE ratio (TTM)12.22
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • PR Newswire

    Protalix BioTherapeutics Reports First Quarter 2024 Financial and Business Results

    Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended March 31, 2024, and provided a business and clinical update.

  • PR Newswire

    Protalix BioTherapeutics to Announce First Quarter 2024 Financial and Business Results on May 10, 2024

    Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will release its financial results for the quarter ended March 31, 2024 and provide a business and clinical update on May 10, 2024.

  • PR Newswire

    Protalix BioTherapeutics Reports Fiscal Year 2023 Financial and Business Results

    Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the fiscal year ended December 31, 2023, and provided a business update.